The health-care industry is looking to harness big data, but finding the right workers isn't always easy. In some cases, companies are making acquisitions to bring talent in-house.» Read More
Genentech investors who were hoping Roche would shed a little more light on the status of its proposed acquisition of the biotech giant might have hung up from the Swiss drugmaker's conference call a little disappointed.
With oil prices lower and a recession coming on, this might be the stock to own.
Why'd this stock drop so quickly? The CEO explains.
Despite a slowing economy, drug stocks such as Abbott Labs and Genentech posted positive earnings reports. Is health care the best defensive play in this market?
As we head into the weekend (TGIF, right?), I wanted to clean out the ol' inbox.
Although the health care industry is not immune to a sluggish economy, the sector presents some attractive opportunities, said Carl McDonald, a senior analyst at Oppenheimer & Co.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.
Stocks leaped on Thursday, as investors snapped up beaten-down shares.
On the Genentech third quarter earnings conference call analysts, investors and reporters were hoping to get some color on the status of the Roche play for the rest of DNA it doesn't already own.
Don't blindly chase this bounce. Be smart and know the playbook to battle the bear.
Food and farming plays like Monsanto, Potash, Yara and Syngenta are good buys, along with health-care stocks such as Essilor, Stephen Pope, chief global market strategist at Cantor Fitzgerald Europe, told CNBC.
Since there should really be no compelling reason to blog or report on Dendreon and Provenge for quite awhile, here's one last hurrah.
In my reporting, I always try to keep it simple. Particularly in the middle of the credit crisis, too much financial jargon goes over the heads of most people. The same can be said for biopharma coverage.
A study presented to the House Steering Committee on Telehealth and Healthcare Informatics earlier this year cited that the country's health care system will require 40,000 additional health IT professionals (close to 40 percent) as the nation moves toward wider IT adoption.
Pretty much all of biopharma is caught in the downdraft of the markets today with the notable exception of Dendreon (data) and ImClone Systems (a deal).
Amid the market melee, you may be starting to question the investment strategy behind your battered portfolio, but before you attempt any knee-jerk moves to mitigate risk, consider the impact an uber conservative investment stance might have on your ability to feather your nest egg.
Okay, what were the chances that ImClone would get bought and Dendreon would come out with its interim test results on the same morning? Slim to none, I'd say. But that's exactly what the news gods had in store for two of the hottest names in biotech.
As all eyes remain on Capitol Hill, things remain relatively quiet on the biopharma front. So, it's a good time to go through the Pharma's Market mailbag. The overwhelming majority of emails recently have been about...yeah, you guessed it...Dendreon.
Energy stocks have gotten hammered recently, but Scott Richter, of the Fifth Third All Cap Value Fund, sees opportunities in the sector.
"The Wall Street Journal" unmasked the identity--Eli Lilly--of ImClone's secret suitor. A spokesman for LLY said he couldn't confirm or deny the report. IMCL put out a press release last night saying that the mystery bidder has asked to remain anonymous.